Dr. Daniel S. Chen is the Chief Medical Officer at IGM Biosciences. Dr. Chen’s expertise lies in the post-treatment analysis of anti-tumor immune responses, specifically in characterizing them so that more effective immunotherapy approaches can be developed for patients. He’s also developed, and continues to develop, tools to improve these analytic capabilities. Dr. Chen is the co-chairman of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.
We’re only beginning to scratch the surface of the possibilities in cancer immunotherapy … and I believe that eventually [they] will become as personalized as targeted therapies, but the science is still young. … The good news is that the science is moving quickly.
Let's spread the word about Immunotherapy! Click to share this page with your community.